Lexeo Therapeutics, Inc.

LXEO Nasdaq CIK: 0001907108

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
Business Address 345 PARK AVENUE SOUTH, NEW YORK, NY, 10010
Mailing Address 345 PARK AVENUE SOUTH, NEW YORK, NY, 10010
Phone (212) 547-9879
Fiscal Year End 1231
EIN 854012572

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report February 20, 2026 View on SEC
4 Insider stock transaction report February 20, 2026 View on SEC
4/A Insider transaction amendment February 20, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • Lead gene therapy candidate LX2006 demonstrated safety and a 25% reduction in heart mass in trial patients.
  • Technology platform leverages research from Weill Cornell Medicine to target root causes of heart and brain diseases.
View Analysis

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.